Note: You clicked on an external link, which has been disabled in order to keep your shopping session open.
|Tested species reactivity||Human|
|Published species reactivity||Human|
|Host / Isotype||Mouse / IgG1|
|Immunogen||Human peripheral blood lymphocytes.|
|Contains||0.05% sodium azide|
|Storage Conditions||4° C|
|Tested Applications||Dilution *|
|Immunohistochemistry (Frozen) (IHC (F))||Assay dependent.|
|Western Blot (WB)||Assay dependent.|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
HLA-A belongs to the HLA class I heavy chain paralogues. This class I molecule is a heterodimer consisting of a heavy chain and a light chain (beta-2 microglobulin). The heavy chain is anchored in the membrane. Class I molecules play a central role in the immune system by presenting peptides derived from the endoplasmic reticulum lumen. They are expressed in nearly all cells. The heavy chain is approximately 45 kDa and its gene contains 8 exons. Exon 1 encodes the leader peptide, exons 2 and 3 encode the alpha1 and alpha2 domains, which both bind the peptide, exon 4 encodes the alpha3 domain, exon 5 encodes the transmembrane region, and exons 6 and 7 encode the cytoplasmic tail. Polymorphisms within exon 2 and exon 3 are responsible for the peptide binding specificity of each class one molecule. Typing for these polymorphisms is routinely done for bone marrow and kidney transplantation. Hundreds of HLA-A alleles have been described.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
Differential pathways govern CD4+ CD28- T cell proinflammatory and effector responses in patients with coronary artery disease.
MA1-35410 was used in blocking or activating experiment to investigate the role of CD4+ CD28- T cells in the development of coronary artery disease
|Zal B,Kaski JC,Akiyu JP,Cole D,Arno G,Poloniecki J,Madrigal A,Dodi A,Baboonian C||Journal of immunology (Baltimore, Md. : 1950) (181:5233)||2008|
Identification of new MHC-restriction elements for presentation of the p210(BCR-ABL) fusion region to human cytotoxic T lymphocytes.
MA1-35410 was used in blocking or activating experiment to investigate the immune response against the p210(BCR-ABL) fusion region in chronic myelogenous leukemia
|Sun JY,Senitzer D,Forman SJ,Chatterjee S,Wong KK||Cancer immunology, immunotherapy : CII (52:761)||2003|
IFN-gamma production dominates the early human natural killer cell response to Coxsackievirus infection.
MA1-35410 was used in flow cytometry to examine the role of interferon gamma during the initial natural killer cell response to Coxsackievirus infection
|Hühn MH,Hultcrantz M,Lind K,Ljunggren HG,Malmberg KJ,Flodström-Tullberg M||Cellular microbiology (10:426)||2008|
Inhibition of heavy chain and beta2-microglobulin synthesis as a mechanism of major histocompatibility complex class I downregulation during Epstein-Barr virus replication.
MA1-35410 was used in flow cytometry to investigate the mechanism of major histocompatibility complex class I downregulation during epstein-barr virus replication
|Guerreiro-Cacais AO,Uzunel M,Levitskaya J,Levitsky V||Journal of virology (81:1390)||2007|
Loss of heterozygosity in the HLA class I region in human pancreatic cancer.
MA1-35410 was used in immunohistochemistry to study loss of heterozygosity in the HLA class I region in 24 patients with ductal pancreatic carcinoma
|Ryschich E,Cebotari O,Fabian OV,Autschbach F,Kleeff J,Friess H,Bierhaus A,Büchler MW,Schmidt J||Tissue antigens (64:696)||2004|
A single polymorphic residue within the peptide-binding cleft of MHC class I molecules determines spectrum of tapasin dependence.
MA1-35410 was used in immunoprecipitation to study the effect of the nature of the polymorphic amino acid at position 114 in the peptide-binding cleft of MHC class I on the tapasin-dependence of peptide loading
|Park B,Lee S,Kim E,Ahn K||Journal of immunology (Baltimore, Md. : 1950) (170:961)||2003|
A29 protein; antigen presenting molecule; DAQB-90C11.16; FLJ26655; HLA A; HLA class I antigen; HLA class I histocompatibility antigen, A-30 alpha chain; HLA class I histocompatibility antigen, A-33 alpha chain; HLA class I histocompatibility antigen, A-74 alpha chain; HLA locus; HLA-A locus alpha 2 domain; HLA-A null; HLA-Aw33.1; HLAA; leukocyte antigen class I-A; MCH class I antigen; MHC class 1 antigen; MHC class I anti; MHC Class I antigen; MHC class I antigen A*30; MHC class I antigen A*33; MHC class I antigen A*74; MHC class I antigen heavy chain; MHC class I antigen HLA-A heavy chain; MHC class I antigen HLA-A33; MHC class I antigen null protein; MHC class I antigene; MHC class II antigen; MHC classI antigen; truncated MHC class I antigen
Aw-33; Aw-74; HLA-A; HLA-A11; HLA-A33; HLA-DQB1; HLA-DRB1; HLAA